2027 ICD-10-CM Diagnosis Code D3A.8Other benign neuroendocrine tumors

ICD-10-CM Codes›C00–D49›D3A›D3A

ICD-10-CM D3A.8
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

D3A.8 is a billable ICD-10-CM diagnosis code for other benign neuroendocrine tumors. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 826 through 830, 843 through 845. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Benign neoplasms.

For Medicare Advantage risk adjustment, D3A.8 maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers) under the V28 model, adding a risk factor of about 0.363 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
D3A.8
Billable Status
Yes — Valid for Submission
Code Describes
Other benign neuroendocrine tumors
Short Description
Other benign neuroendocrine tumors
Same as the full description in the CMS dataset.
Parent Code
D3A
Benign neuroendocrine tumors

Code Classification

ChapterC00–D49Neoplasms
SectionD3ABenign neuroendocrine tumors
CategoryD3ABenign neuroendocrine tumors
This CodeD3A.8Other benign neuroendocrine tumors

Medicare Risk Adjustment (HCC)Billing

D3A.8 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 22— Bladder, Colorectal, and Other Cancers
Payment HCC · PY 2027 one of 126 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.363
community, non-dual, aged · ranges 0.314–0.410 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
Not mapped under V24
this diagnosis newly risk-adjusts under the V28 model
Part D (RxHCC)
RxHCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • 5-HT secreting neuroendocrine tumor
  • Benign neoplasm of appendix
  • Benign neoplasm of cecum
  • Benign neoplasm of rectum
  • Benign neoplasm of superior mediastinum
  • Benign neoplasm of thymus
  • Benign neuroendocrine neoplasm of bronchus
  • Benign neuroendocrine neoplasm of liver
  • Benign neuroendocrine neoplasm of thymus
  • Benign neuroendocrine tumor
  • Benign neuroendocrine tumor of appendix
  • Benign neuroendocrine tumor of cecum
  • Benign neuroendocrine tumor of duodenum
  • Benign neuroendocrine tumor of kidney
  • Benign neuroendocrine tumor of lung
  • Benign neuroendocrine tumor of rectum
  • Benign neuroendocrine tumor of small intestine
  • Benign neuroendocrine tumor of stomach
  • Benign perivascular epithelioid cell neoplasm
  • Gastrointestinal hormone-secreting endocrine tumor
  • Neonatal malabsorption with gastrointestinal hormone-secreting endocrine tumor
  • Neuroendocrine neoplasm
  • Neuroendocrine neoplasm of appendix
  • Neuroendocrine neoplasm of colon
  • Neuroendocrine neoplasm of duodenum
  • Neuroendocrine neoplasm of gallbladder
  • Neuroendocrine neoplasm of gastrointestinal tract
  • Neuroendocrine neoplasm of larynx
  • Neuroendocrine neoplasm of lung
  • Neuroendocrine neoplasm of rectum
  • Neuroendocrine neoplasm of small intestine
  • Neuroendocrine neoplasm of stomach
  • Neuroendocrine tumor of middle ear
  • Nonhyperfunctioning neuroendocrine tumor
  • Pancreatic polypeptidoma
  • Well-differentiated neuroendocrine tumor of anus
  • Well-differentiated neuroendocrine tumor of pancreas

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to D3A.8: its own notes plus those printed at D3A, block D37-D48, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Neuroendocrine tumor NOS

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From Block D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes applies to 137 codes
  • neoplasms of unspecified behavior (D49.-)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From D3A Benign neuroendocrine tumors applies to 22 codes
  • benign pancreatic islet cell tumors (D13.7)

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From D3A Benign neuroendocrine tumors applies to 22 codes
  • code to identify any associated endocrine syndrome, such as:
  • carcinoid syndrome (E34.00)

Code Also

A second code may be needed to fully describe the condition; the note gives no sequencing direction.

From D3A Benign neuroendocrine tumors applies to 22 codes
  • any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)

Notes

General instructions on how these codes are used.

From Block D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes applies to 137 codes
  • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
From Chapter 2 (C00-D49) Neoplasms applies to 1,730 codes
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name D3A.8, its category, or a range that includes it.

Excludes2 1

These codes carry an Excludes2 note naming D3A.8: its condition is not part of those codes, and both may be reported when the patient has both.

  • D49 Neoplasms of unspecified behavior
    neoplasms of uncertain behavior (D37-D44, D48) names D37-D44, which includes this code

Notes 1

These notes mention D3A.8.

  • Block D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
    Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made. names D37-D44, which includes this code

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO073
Benign neoplasms
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Benign Tumors

Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D3A.8 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
209.60 Ben crcnd prim site unkn
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About D3A.8Overview

What is the ICD-10 code for other benign neuroendocrine tumors?

The ICD-10-CM code for other benign neuroendocrine tumors is D3A.8 (sometimes written as D3A8). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is D3A.8 (Benign neuroendocrine tumors) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other benign neuroendocrine tumors on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does D3A.8 group to?

When other benign neuroendocrine tumors is the principal diagnosis on an inpatient stay, it groups to MS-DRG 844, 827, 829, 843, 828, 826, 830, 845, with relative weights from 0.8443 to 4.7560 depending on complications. Higher weights mean higher Medicare reimbursement.

Can D3A.8 be reported with a code from D49?

Not as a rule. The Excludes1 note at block D37-D48, which applies to D3A.8, lists "neoplasms of unspecified behavior (D49.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

Does D3A.8 need an additional code?

When the condition applies, yes. The Use Additional Code note at D3A, which applies to D3A.8, reads: code to identify any associated endocrine syndrome, such as: carcinoid syndrome (E34.00). The additional code is reported after D3A.8.

What HCC is D3A.8?

D3A.8 (other benign neuroendocrine tumors) maps to CMS-HCC Category 22 (Bladder, Colorectal, and Other Cancers), commonly written as HCC 22, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. In the Part D prescription drug model it maps to RxHCC 22.

Does D3A.8 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, D3A.8 adds a risk adjustment factor of about 0.363 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.314 to 0.410 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, and HCC 21) supersedes it when both are reported. See the full factor table on the HCC 22 category page.